35
Participants
Start Date
November 1, 2023
Primary Completion Date
May 1, 2024
Study Completion Date
September 30, 2024
Dry Needling
Group A will undergo dry needling sessions twice a week over eight weeks, specifically targeting trigger points and tender points. Simultaneously, a consistent dosage of selective serotonin reuptake inhibitor (SSRI) will be administered and maintained throughout the entire duration of the study.
Trigger points injections
Group B will undergo a comprehensive intervention involving trigger point injections administered biweekly over eight weeks. These injections will specifically target trigger points. Additionally, a control measure will be implemented through simulated needling at non-specific points.
serotonin reuptake inhibitor (SSRI)
serotonin reuptake inhibitor (SSRI)
Chaudary Muhammad Akram Teaching Hospital, Lahore
Superior University
OTHER